Christopher P Leamon - Net Worth and Insider Trading
Christopher P Leamon Net Worth
The estimated net worth of Christopher P Leamon is at least $3 Million dollars as of 2024-12-27. Christopher P Leamon is the Vice President of Research of Endocyte Inc and owns about 121,353 shares of Endocyte Inc (ECYT) stock worth over $3 Million. Details can be seen in Christopher P Leamon's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher P Leamon has not made any transactions after 2018-10-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher P Leamon
Christopher P Leamon Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher P Leamon owns 1 companies in total, including Fusion Pharmaceuticals Inc (FUSN) .
Click here to see the complete history of Christopher P Leamon’s form 4 insider trades.
Insider Ownership Summary of Christopher P Leamon
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
FUSN | Fusion Pharmaceuticals Inc | 2021-11-01 | Chief Scientific Officer |
Christopher P Leamon Latest Holdings Summary
Christopher P Leamon currently owns a total of 1 stock. Christopher P Leamon owns 121,353 shares of Endocyte Inc (ECYT) as of October 5, 2018, with a value of $3 Million.
Latest Holdings of Christopher P Leamon
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ECYT | Endocyte Inc | 2018-10-05 | 121,353 | 23.99 | 2,911,258 |
Holding Weightings of Christopher P Leamon
Christopher P Leamon Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher P Leamon has made a total of 0 transactions in Endocyte Inc (ECYT) over the past 5 years. The most-recent trade in Endocyte Inc is the sale of 9,028 shares on October 5, 2018, which brought Christopher P Leamon around $140,476.
Insider Trading History of Christopher P Leamon
- 1
Christopher P Leamon Trading Performance
GuruFocus tracks the stock performance after each of Christopher P Leamon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher P Leamon is 68.05%. GuruFocus also compares Christopher P Leamon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher P Leamon within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Christopher P Leamon's insider trading performs compared to the benchmark.
Performance of Christopher P Leamon
Christopher P Leamon Ownership Network
Christopher P Leamon Owned Company Details
What does Fusion Pharmaceuticals Inc do?
Who are the key executives at Fusion Pharmaceuticals Inc?
Christopher P Leamon is the Chief Scientific Officer of Fusion Pharmaceuticals Inc. Other key executives at Fusion Pharmaceuticals Inc include Chief Medical Officer Dmitri Bobilev , director & Chief Executive Officer John Valliant , and President and CBO Mohit Rawat .
Fusion Pharmaceuticals Inc (FUSN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Fusion Pharmaceuticals Inc (FUSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fusion Pharmaceuticals Inc (FUSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Fusion Pharmaceuticals Inc (FUSN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Fusion Pharmaceuticals Inc Insider Transactions
Christopher P Leamon Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher P Leamon. You might contact Christopher P Leamon via mailing address: C/o Fusion Pharmaceuticals Inc., 2 International Place Suite 2310, Boston Ma 02110.